4.7 Article

Development and characterization of a colon PDX model that reproduces drug responsiveness and the mutation profiles of its original tumor

Journal

CANCER LETTERS
Volume 345, Issue 1, Pages 56-64

Publisher

ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2013.11.010

Keywords

Patient derived xenograft (PDX); Colon cancer; Oncomap analysis; Primary culture; Drug sensitivity

Categories

Funding

  1. Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea [A062254]
  2. National Research Foundation of Korea
  3. Korean Government (Ministry of Education, Science and Technology) [NRF-355-2010-1-C00071]
  4. Leading Foreign Research Institute Recruitment Program through the National Research Foundation of Korea (NRF)
  5. Ministry of Education, Science and Technology (MEST) [2011-0030105]

Ask authors/readers for more resources

Cultures of primary tumors are very useful as a personalized screening system for effective therapeutic options. We here describe an effective method of reproducing human primary colon tumors through primary culture and a mouse xenograft model. A total of 199 primary colon tumor cultures were successfully established under optimized conditions to enrich for tumor cells and to expand it for long-term storage in liquid nitrogen. To examine whether these stored cultures retained original tumor properties, fifty primary cultures were xenografted into NOD-SCID mouse. Histological and tumor marker analysis of four representative tumor xenografts revealed that all of the xenograft retained its primary tumor characteristics. Oncomap analysis further showed no change in the major mutations in the xenografts, confirming that our method faithfully reproduced human colon tumors. A drug sensitivity assay revealed that two of the primary cultures were hypersensitive to oxaliplatin rather than 5-FU, which was used in the patients, suggesting it as an effective therapeutic option. We thus present an effective, reproducible preclinical model for testing various personalized therapeutic options in colon cancer patients. (C) 2013 Elsevier Ireland Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available